Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antigenics Improves Oncophage Vaccine Manufacturing Output Ahead Of Registration Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Non-registration Phase III trial shows extension in survival for Oncophage-treated arm in category M1a stage IV melanoma.

You may also be interested in...



Antigenics Will Collect Survival Data Before Taking Next Steps With Oncophage Vaccine

Antigenics will work with FDA to determine an appropriate path to market for the kidney cancer vaccine, but the firm says it would need a partner if another trial is needed.

Antigenics Will Collect Survival Data Before Taking Next Steps With Oncophage Vaccine

Antigenics will work with FDA to determine an appropriate path to market for the kidney cancer vaccine, but the firm says it would need a partner if another trial is needed.

Intracel OncoVAX Phase III Will Follow Patients For Three Years

Firm says single pivotal trial of the autologous cancer vaccine can support a BLA for adjuvant treatment of Stage II colon cancer.

Related Content

Topics

UsernamePublicRestriction

Register

PS061070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel